# PD-1 Antibody in Addition to BACE in Patients With NSCLC: A Randomised Controlled Trial

> **NCT05605613** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Xuhua Duan** · enrollment: 150 (estimated)

## Conditions studied

- NSCLC

## Interventions

- **DRUG:** PD-1 Antibody
- **DEVICE:** BACE

## Key facts

- **NCT ID:** NCT05605613
- **Lead sponsor:** Xuhua Duan
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-10-29
- **Primary completion:** 2023-11-15
- **Final completion:** 2025-12-01
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2022-11-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05605613

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05605613, "PD-1 Antibody in Addition to BACE in Patients With NSCLC: A Randomised Controlled Trial". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05605613. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*